Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure

Nutrition

Volumn 31, Issue 1, 2015, Pages 72-78

  Lombardi, Carlo ^a   Carubelli, Valentina ^a   Lazzarini, Valentina ^a   Vizzardi, Enrico ^a   Bordonali, Tania ^a   Ciccarese, Camilla ^a   Castrini, Anna Isotta ^a   Dei Cas, Alessandra ^a   Nodari, Savina ^a   Metra, Marco ^a  

^a and Public Health University and Civil Hospital of Brescia ^*  (Italy)

Author keywords

Amino acids; Cardiopulmonary exercise test; Chronic heart failure; Levo carnosine; Micronutrient; Quality of life

Indexed keywords

CARNOSINE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE BLOOD LEVEL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MIDDLE AGED; MORNING DOSAGE; OPEN STUDY; OXYGEN TENSION; PARALLEL DESIGN; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; AGED; ANAEROBIC THRESHOLD; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; EXERCISE TEST; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FUNCTION; METABOLISM; ORAL DRUG ADMINISTRATION; WALKING;

ADMINISTRATION, ORAL; AGED; ANAEROBIC THRESHOLD; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; CARNOSINE; CHOLESTEROL; CHRONIC DISEASE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT; WALKING;

EID: 84922277301     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.04.021     Document Type: Article

References (56)

1. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869. ESC Committee for Practice Guidelines.
2. Piña I.L., Apstein C.S., Balady G.J., Belardinelli R., Chaitman B.R., Duscha B.D., et al. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003, 107:1210-1225. American Heart Association Committee on exercise, rehabilitation, and prevention.
3. McKeag N.A., McKinley M.C., Woodside J.V., Harbinson M.T., McKeown P.P. The role of micronutrients in heart failure. J Acad Nutr Diet 2012, 112:870-886.
4. Soukoulis V., Dihu J.B., Sole M., Anker S.D., Cleland J., Fonarow G.C., et al. Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol 2009, 54:1660-1673.
5. Pasini E., Aquilani R., Gheorghiade M., Dioguardi F.S. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J 2003, 4:232-235.
6. Aquilani R., Viglio S., Iadarola P., Opasich C., Testa A., Dioguardi F.S. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 2008, 101:104E-110E.
7. Orozco-Gutiérrez J.J., Castillo-Martínez L., Orea-Tejeda A., Vázquez-Díaz O., Valdespino-Trejo A., Narváez-David R., et al. Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J 2010, 17:612-618.
8. Witte K.K., Nikitin N.P., Parker A.C., von Haehling S., Volk H.D., Anker S.D., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005, 26:2238-2244.
9. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
10. Ingwall J.S. On the hypothesis that the failing heart is energy starved: lessons learned from the metabolism of ATP and creatine. Curr Hypertens Rep 2006, 8:457-464.
11. Tuunanen H., Ukkonen H., Knuuti J. Myocardial fatty acid metabolism and cardiac performance in heart failure. Curr Cardiol Rep 2008, 10:142-148.
12. Taegtmeyer H., Harinstein M.E., Gheorghiade M. More than bricks and mortar: comments on protein and amino acid metabolism in the heart. Am J Cardiol 2008, 101:3E-7E.
13. Stuenenburg H.J., Kunze K. Concentration of free carnosine (a putative membrane-protective antioxidant) in human muscle biopsies and rat muscles. Arch Gerontol Geriatrics 1999, 29:107-113.
14. Johnson P., Fedyna J.S., Schindzielorz A., Smith C.M., Kasvinshy P.J. Regulation of muscle phosphorylase activity by carnosine and anserine. Biochem Biophys Res Commun 1982, 109:769-775.
15. Kohen R., Yamamoto Y., Cundy K.C., Ames B. Antioxidant activity of carnosine, homocarnosine and anserine present in muscle and brain. Proc Natl Acad Sci U S A 1998, 95:2175-2179.
16. Hipkiss A.R. Carnosine, a protective anti-ageing peptide?. Int J Biochem Cell Biol 1998, 30:863-868.
17. McFarland G.A., Holliday R. Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp Gerontol 1999, 34:35-45.
18. Hipkiss A.R., Holliday R., McFarland G., Michaelis J. Carnosine and senescence. Lifespan 1993, 4:1-3.
19. Boldyrev A.A., Stvolinskiĭ S.L., Fedorova T.N. Carnosine: endogenous physiological corrector of antioxidative system activity. Usp Fiziol Nauk 2007, 38:57-71.
20. Gallant S., Semyonova M., Yuneva M. Carnosine as a potential anti-senescence drug. Biochemistry 2000, 65:866-868.
21. Hipkiss A.R., Michaelis J., Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS 1995, 371:81-85.
22. Kim M.Y., Kim E.J., Kim Y.N., Choi C., Lee B.H. Effects of α-lipoic acid and l-carnosine supplementation on antioxidant activities and lipid profiles in rats. Nutr Res Pract 2011, 5:421-428.
23. Janssen B., Hohenadel D., Brinkkoetter P., Peters V., Rind N., Fischer C., et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005, 54:2320-2327.
24. Everaert I., Taes Y., De Heer E., Baelde H., Zutinic A., Yard B., et al. Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans. Am J Physiol Renal Physiol 2012, 302:F1537-F1544.
25. McDonough C.W., Hicks P.J., Lu L., Langefeld C.D., Freedman B.I., Bowden D.W., et al. The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. Hum Genet 2009, 126:265-275.
26. Kiliś-Pstrusińska K. Carnosine, carnosinase and kidney diseases. Postepy Hig Med Dosw (Online) 2012, 66:215-221.
27. Snimoniia G.V., Tatishvili N.I., Shiliia D.S.H., Bakanidze N.T., Khachidze M.V. The effect of carnosine on the activity of Na, K, ATPase: prospective uses in clinical cardiology. Biokhimiia 1992, 57:1343-1347.
28. Zieba R., Wagrowska-Danilewicz M. Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits. Pol J Pharmacol 2003, 55:1079-1087.
29. Hultman E., Sahlin K. Acid-base balance during exercise. Exerc Sports Sci Rev 1980, 8:41-128.
30. Culbertson J.Y., Kreider R.B., Greenwood M., Cooke M. Effects of beta-alanine on muscle carnosine and exercise performance: a review of the current literature. Nutrients 2010, 2:75-98.
31. Caruso J., Charles J., Unruh K., Giebel R., Learmonth L., Potter W. Ergogenic effects of β-alanine and carnosine: proposed future research to quantify their efficacy. Nutrients 2012, 4:585-601.
32. Baguet A., Koppo K., Pottier A., Derave W. Alanine supplementation reduces acidosis but not oxygen uptake response during high-intensity cycling exercise. Eur J Appl Physiol 2010, 108:495-503.
33. Batrukova M.A., Rubtsov A.M. Histidine-containing dipeptides as endogenous regulators of the activity of sarcoplasmic reticulum Ca-release channels. Biochim Biophys Acta 1997, 1324:142-150.
34. Ririe D.G., Roberts P.R., Shouse M.N., Zaloga G.P. Vasodilatory actions of the dietary peptide carnosine. Nutrition 2000, 16:168-172.
35. Zaloga G.P., Roberts P.R., Black K.W., Lin M., Zapata-Sudo G., Sudo R.T., et al. Carnosine is a novel peptide modulator of intracellular calcium and contractility in cardiac cells. Am J Physiol 1997, 272:H462-H468.
36. Good clinical practice for trials on medical products in the European community. CPMP Working party on efficacy of medical products 91/507/EC. Pharmacol Toxicol 1990, 67:361-372.
37. Baraniuk J.N., El-Amin S., Corey R., Rayhan R., Timbol C. Carnosine treatment for gulf war illness: a randomized controlled trial. Glob J Health Sci 2013, 5:69-81.
38. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. EuroQol Group.
39. Balestroni G., Omarini G., Omarini P., Zotti A.M. EuroQol-5D FOR quality of life assessment in cardiac rehabilitation. G Ital Med Lav Ergon 2007, 29:B56-B62.
40. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
41. Stevenson L.W. Role of exercise testing in the evaluation of candidates for cardiac transplantation. Exercise Gas Exchange in Heart Disease 1996, 271-286. Futura Publishing Company, Armonk, NY. K. Wasserman (Ed.).
42. Weber K.T., Kinasewitz G.T., Janicki J.S., Fishman A.P. Oxygen utilization and ventilation during exercise in patients with chronic heart failure. Circulation 1982, 65:1213-1223.
43. Guyatt D.J., Sullivan M.J., Thompson P.J., Fallen E.L., Pugsley S.O., Taylor D.W., et al. The 6-minutes walk: a measure of exercise capacity in patients with chronic heart failure. Can med Assoc J 1985, 132:919-923.
44. Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.
45. Dolan P.D. Modelling Valuations for EuroQol Health States. Med Care 1997, 35:1095-1108.
46. Carubelli V., Castrini A.I., Lazzarini V., Gheorghiade M., Metra M., Lombardi C. Amino acids and derivatives, a new treatment of chronic heart failure?. Heart Fail Rev 2014 Jun 13, [Epub ahead of print].
47. Trippel T.D., Anker S.D., von Haehling S. The role of micronutrients and macronutrients in patients hospitalized for heart failure. Heart Fail Clin 2013, 9:354-357.
48. Anand I., Chandrashekhan Y., De Giuli F., Pasini E., Mazzoletti A., Confortini R., et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998, 12:291-299.
49. Aquilani R., Opasich C., Gualco A., Verri M., Testa A., Pasini E., et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail 2008, 10:1127-1135.
50. Lombardi C., Carubelli V., Lazzarini V., Vizzardi E., Quinzani F., Guidetti F., et al. Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. Clin Med Insights Cardiol 2014 May 21, 8:39-44.
51. Balderas-Munoz K., Castillo-Martínez L., Orea-Tejeda A., Infante-Vázquez O., Utrera-Lagunas M., Martínez-Memije R., et al. Improvement of ventricular function in systolic heart failure patients with oral L-citrulline supplementation. Cardiol J 2012, 19:612-617.
52. Parkhouse W.S., McKenzie D.C., Hochachka P.W., Ovalle W.K. Buffering capacity of deproteinized human vastus lateralis muscle. J Appl Physiol 1985, 58:14-17.
53. Hobson R.M., Saunders B., Ball G., Harris R.C., Sale C. Effects of β-alanine supplementation on exercise performance: a review by meta-analysis. Amino Acids 2012, 43:25-37.
54. Smith-Ryan A.E., Fukuda D.H., Stout J.R., Kendall K.L. High velocity intermittent running: effects of beta-alanine supplementation. J Strength Cond Res 2012, 26:2798-2805.
55. Sale C., Saunders B., Harris R.C. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. Amino Acids 2010, 39:321-333.
56. 2+ release in human skeletal muscle fibers. J Appl Physiol 2012, 112:728-736.